Sanofi, Vanda, and GSK, a New Year Voyage through the Land of Induced Infringement
Includes a Live Event on 01/21/2021 at 2:00 PM (EST)
The Federal Circuit decisions in Sanofi v. Watson and Vanda v. Westward provide blue prints for possibly obtaining, based on Phase III clinical trial results, many more years of U.S patent exclusivity. Please join our expert panel of Meg Tomaska of Eli Lilly & Co., Sarah Hooson of Merck & Co. Inc., and Daniela Gill-Carey of UCB Biopharma SRL, moderated by Tom Irving of Finnegan, to learn all about it.
Tom Irving (Moderator)
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Tom Irving is a partner with Finnegan. He has more than 40 years of experience in the field of intellectual property law. His practice includes America Invents Act (AIA) post-grant proceedings, due diligence, counseling, patent prosecution, and reissue and reexamination. He counsels clients on a wide range of mainly pharmaceutical matters, including pre-litigation, Orange Book listings of patents covering FDA-approved drugs, infringement issues, enforceability and validity analysis.
Associate General Patent Counsel
UCB Biopharma SRL
Daniela Gill-Carey holds a dual qualification as a European and as a UK Chartered patent attorney and is currently an associate general patent counsel within the UK IP department of UCB Biopharma. She supports all patent-related activities of various pre-clinical and clinical programs and biopharmaceutical technologies. Daniela started her career in the patent department of Procter and Gamble, before joining the pharmaceutical sector in 2008, first at TEVA and then at Novartis. Prior joining UCB, she led the IP department of Proteome Sciences, a British/German bioscience company. Before entering the patent profession, she received a PhD in Biochemistry from the University of Zurich and a MSc in Intellectual Property Law from the ETH in Zurich (Switzerland).
Director of the Intellectual Property Group
Merck & Co.
Sarah Hooson is director in the Intellectual Property Group at Merck in Rahway, NJ, having gained her initial legal patent experience while working at GlaxoSmithKline (GSK). Sarah’s present responsibilities include patent preparation, prosecution, and due diligence support for small molecule, vaccine, and antibody programs in human and animal health. Sarah received her bachelor’s degree in Biomedical Engineering from Georgia Institute of Technology, and her J.D. from Widener University. Sarah gained considerable bio-pharmaceutical research and development and vaccine process development experience while working as an engineer at Merck, GSK and MedImmune.
Eli Lilly and Co.
Margaret Tomaska is a patent counsel for Eli Lilly and Co. She earned her law degree from Georgetown University and has been with Eli Lilly since May 2018. Previously, she worked for GlaxoSmithKline.